Health Care/Hospital Global News & Press Release Distribution

Health Care/Hospital

All
APAC

2023 ASCO | Multi-center Data for Combination Study of GenFleet's GFH018 (TGF-β R1 inhibitor) with Anti-PD-1 Antibody Demonstrates Significant Potential to Enhance Efficacy of Immune Checkpoint Inhibitors among ICI-naïve Patients

SHANGHAI and CHICAGO, June 6, 2023 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today published the latest results from the phase Ib/II study of GFH018 (TGF-β R1 inhibitor) with toripalimab（anti-PD-1 ...

2023-06-06 19:00 1856

Samsung Biologics accelerates timeline of new fifth plant to be operational by April 2025

- Marking the first phase of the company's second Bio Campus, Plant 5 is expected to have shortest construction timeline - Samsung Biologics will maintain the world's largest biomanufacturing capacity at 784,000 liters upon completion of the newest plant - Key features of Plant 5 include seamless ...

2023-06-06 19:00 1930

Acepodia Secures $100 Million Series D Financing to Advance

First-In-Class Cell Therapies with Antibody-Cell Conjugation (ACC) Platform Series D led by Digital Mobile Venture with participation from additional existing investors Funds will support expansion and progress of oncology pipeline, including ACE1831 and ACE2016, antibody armed allogeneic gamma ...

2023-06-06 18:00 1661

Live from ASCO 2023 | Ascentage Pharma Releases Updated Data Showing APG-2449's Potential as a New Treatment for Drug-Resistant NSCLC

SUZHOU, China and ROCKVILLE, Md., June 6, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that for the second consecutive year, it has release...

2023-06-06 12:20 3034

USANA Malaysia Named Top Combination Dietary Supplements Brand by Euromonitor International

USANA Malaysia awarded for fifth year in a row KUALA LUMPUR, Malaysia, June 6, 2023 /PRNewswire/ -- USANA Malaysia was recently awarded the title Top #1 Combination Dietary Supplements Brand in Malaysia by market research giant Euromonitor International—earning this elite recognition for the fift...

2023-06-06 11:00 2267

Live from ASCO 2023 | Ascentage Pharma Releases the First Dataset of Lisaftoclax in WM, Revealing Encouraging Therapeutic Potential

SUZHOU, China and ROCKVILLE, Md,, June 5, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released preliminary results from a Phas...

2023-06-06 10:45 2009

Cali Biosciences Initiates Second Phase III Study of CPL-01 (Long-Acting Ropivacaine) to Decrease Post-Operative Pain and Reduce or Eliminate Opioid Use and Presents Consistent and Predictable PK Results Across Multiple Surgeries

* Subjects in Bunionectomy Study Dosed * Data Presented at American Society for Pharmacology and Experimental Therapeutics Shows Similar Ropivacaine Pharmacokinetic Curves From CPL-01 Across Multiple Surgeries; Minimal Variability as Compared to Liposomal Bupivacaine SAN DIEGO, June 5, 2023 ...

2023-06-06 00:00 2370

Russellville Hospital and United Imaging Announce First Installation in the U.S. of the 4 cm uCT(R) ATLAS Computed Tomography Scanner

Russellville Hospital Moved Quickly To Bring High-End Technology to Patients HOUSTON, June 5, 2023 /PRNewswire/ -- United Imaging, a global leader in manufacturing advanced medical imaging and radiotherapy equipment, confirmed that Russellville Hospital is the first customer to complete installat...

2023-06-05 22:00 1928

Maternity and Baby Brand Momcozy Launches Cutting-edge M5 Wearable Breast Pump - the Ultimate Solution for Busy Moms

NEW YORK, June 5, 2023 /PRNewswire/ -- Momcozy, the renowned maternity and baby brand endorsed by over two million moms globally, has launched thecutting-edge M5 Wearable Breast Pump

2023-06-05 22:00 1982

Fresh2 Group Ltd. Announces US$4.4 Million Private Placement

NEW YORK, June 5, 2023 /PRNewswire/ -- Fresh2 Group Ltd., formerly AnPac Bio-Medical Science Co., Ltd. (NASDAQ: FRES), a company with operations in the United States and China focused on early cancer screening and detection and plans to enter into the operation of a business-to-business e-commer...

2023-06-05 21:00 2767

Live from ASCO 2023 | For the Third Consecutive Year, Ascentage Pharma Releases Promising Results of Alrizomadlin plus Pembrolizumab in Patients with Cutaneous Melanoma that Failed Immuno-Oncologic (IO) Therapies

SUZHOU, China, and ROCKVILLE, Md., June 5, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released updated results from a Phase I...

2023-06-05 17:34 2108

Lunit and Capio S:t Göran Hospital Collaborate to Address Radiologist Shortage with AI-Powered Mammography Analysis

- Lunit and Sweden's largest private hospital pioneering a new approach to combine radiologists' expertise with AI SEOUL, South Korea, June 5, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading global provider of AI-powered cancer diagnostic solutions, today announced the signing of a supply ...

2023-06-05 15:00 1871

Lunit and Capio S:t Göran Hospital Collaborate to Address Radiologist Shortage with AI-Powered Mammography Analysis

Gencurix Announces Clinical Research Results At ASCO 2023 Demonstrating Outstanding Performance of GenesWell BCT, the Company's Breast Cancer Prognostic Test, Compared to Global Best-Selling Test, OncotypeDX

SEOUL, South Korea, June 4, 2023 /PRNewswire/ -- Gencurix (KOSDAQ #229000), a leading provider of cancer molecular diagnostics, announced the release of clinical research results directly comparing the accuracy of its breast cancer prognostic test, GenesW...

2023-06-05 14:37 2488

American Society of Clinical Oncology confers highest honor upon Prof Hagop Kantarjian

SUZHOU, China and ROCKVILLE, Md., June 5, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that its Clinical Advisory Board member ProfHago...

2023-06-05 12:30 1817

Live from ASCO 2023 | Updated Data of Olverembatinib in SDH-Deficient GIST including a CBR of 93.8% Signals a Potential Clinical Breakthrough

SUZHOU, China and ROCKVILLE, Md., June 4, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released updated clinical results of olv...

2023-06-05 11:51 1967

Harbour BioMed Announces First Patient Dosed in Phase I Study of First-in-Class Anti-B7H7 (HHLA2) Antibody HBM1020

* HBM1020 is a first-in-class therapeutic monoclonal antibody against B7H7/HHLA2 entering clinical development globally. * HBM1020 was generated from Harbour Mice® H2L2 transgenic mice platform. * HBM1020 has great potential to address huge unmet medical needs in patients with advanced malig...

2023-06-05 09:01 1863

LOTTE BIOLOGICS to Kick off their CDMO Business Campaign at 'BIO International Convention 2023'

* Exclusive booth and private meeting rooms to be utilized for robust business initiatives SEOUL, South Korea, June 4, 2023 /PRNewswire/ -- LOTTE BIOLOGICS, under the leadership of CEORichard Lee, enthusiastically disclosed its participation in the upcoming 'BIO International Convention 2023' t...

2023-06-05 08:27 2009

LOTTE BIOLOGICS to Kick off their CDMO Business Campaign at 'BIO International Convention 2023'

VVN539 met primary study endpoints in US phase IIa clinical study for the treatment of glaucoma

SHANGHAI, June 4, 2023 /PRNewswire/ -- This was a Phase 2, double-masked, randomized, vehicle-controlled, dose-response study to assess the safety and ocular hypotensive efficacy of VVN539 in subjects with primary open angle glaucoma (POAG) or ocular hypertension (OHT). The primary objective was ...

2023-06-05 08:00 1990

Gracell Biotechnologies Presents Updated Data of Deep and Durable Responses for FasTCAR-T GC012F in Relapsed/Refractory Multiple Myeloma at 2023 ASCO Annual Meeting

Data on BCMA/CD19 dual-targeting FasTCAR-T GC012F showed 100% minimal residual disease (MRD) negativity and 82.8% MRD negative stringent complete response (sCR) in a predominantly high-risk relapsed/refractory multiple myeloma (RRMM) population Data on GC012F for treatment of B-NHL will be prese...

2023-06-04 02:15 3222

Sanyou launches new European offices and continues to promote global business landscape

SHANGHAI, June 3, 2023 /PRNewswire/ -- In May 2023, following the CIC Boston branch in US, Sanyou opens new offices in The Shard London and CIC Rotterdam respectively, to rapidly promote the globalization of business landscape. Headquartered in Shanghai China, Sanyou Biopharmaceuticals Co., Ltd. ...

2023-06-03 20:05 3311

1 ... 52 53 545556 57 58 ... 253